Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech's SNK01 NK Cells

Stable disease was observed in three out of seven heavily pretreated patientsNo dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 -- Affimed N.V. ...

Related Keywords

Heidelberg ,Baden Wüberg ,Germany ,Yokohama ,Kanagawa ,Japan ,Russia ,Texas ,United States ,New York ,Ukraine ,Anthony El Khoueiry ,Andreas Harstrick ,Anthonyb El Khoueiry ,Alexander Fudukidis ,Mary Beth Sandin ,Phasei Program ,University Of Texas Md Anderson Cancer Center ,Norris Comprehensive Cancer Center ,Clinical Research ,Associate Director ,Phasei Program Director ,Comprehensive Cancer Center ,Chief Medical Officer ,Poster Session ,Cancer Center ,Markets ,